FDA Reiterates No Changes to Covid-19 Vaccine Dosing Schedules in the US

The US Food and Drug Administration (FDA) has confirmed that it does not plan to make any changes to Covid-19 vaccine dosing schedules in the United States, citing the lack of evidence and potential risks associated with altering the recommended dosing. This stance has been reinforced by health officials, including the Infectious Diseases Society of America, which has expressed concerns about the potential consequences of altering vaccine dosing.

Key Takeaways:

• The FDA has stated that it does not plan to make any changes to Covid-19 vaccine dosing schedules in the US, citing the lack of evidence and potential risks associated with altering the recommended dosing.
• Health officials, including the Infectious Diseases Society of America, have expressed concerns about the potential consequences of altering vaccine dosing, including undermining the effectiveness of vaccines and eroding public trust.
• The overall development of Covid-19 vaccines, including dosing schedules and the process of getting them into arms, has been unprecedented, with scientists and health officials working at an unprecedented pace to combat the pandemic.
• FDA Commissioner Dr. Stephen Hahn and Dr. Peter Marks, who heads FDA's vaccine division, have issued a statement emphasizing that suggesting changes to vaccine dosing schedules is premature and not rooted in available evidence.
• In Britain, medical officers have extended the 21-day period between administering the first and second doses of the Pfizer/BioNTech Covid-19 vaccine in order to stretch the vaccine supply, but Pfizer has stated that there are no data to demonstrate that just a single dose of the vaccine would provide protection against the disease after more than 21 days.
• The Infectious Diseases Society of America has noted that the nation is facing obstacles and challenges with rolling out Covid-19 vaccines, but agrees with the FDA that changes to authorized use of the vaccines would be premature and potentially harmful.
• Emerson University's David Benkeser has stated that changes to vaccine dosing schedules would likely be submitted to the FDA for consideration and then the agency would review data supporting such changes.
• Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has emphasized the importance of being cautious and patient in the rollout of Covid-19 vaccines, noting that the rollout is expected to pick up momentum in the coming weeks.

Statistics:

• According to Pfizer, the Phase 3 study for the Covid-19 vaccine was designed to evaluate the vaccine's safety and efficacy following a two-dose schedule, separated by 21 days.
• There are no data to demonstrate that protection after the first dose is sustained after 21 days, according to Pfizer.
• The Infectious Diseases Society of America has noted that the nation is facing obstacles and challenges with rolling out Covid-19 vaccines, but agrees with the FDA that changes to authorized use of the vaccines would be premature and potentially harmful.
• The FDA has stated that it does not plan to make any changes to Covid-19 vaccine dosing schedules in the US, citing the lack of evidence and potential risks associated with altering the recommended dosing.
• The overall development of Covid-19 vaccines, including dosing schedules and the process of getting them into arms, has been unprecedented, with scientists and health officials working at an unprecedented pace to combat the pandemic.

Sources:

• CNN
• FDA Commissioner Dr. Stephen Hahn and Dr. Peter Marks, FDA's vaccine division
• Infectious Diseases Society of America
• Emerson University's David Benkeser
• Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases
• Pfizer
• New York Times' Newsday